- Home
- ASMB vs VGI Comparison
ASMB vs VGI Comparison
Compare ASMB & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- VGI
- Stock Information
- Founded
- ASMB 2005
- VGI 2012
- Country
- ASMB United States
- VGI United States
- Employees
- ASMB N/A
- VGI N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- ASMB Health Care
- VGI Finance
- Exchange
- ASMB Nasdaq
- VGI Nasdaq
- Market Cap
- ASMB 138.4M
- VGI N/A
- IPO Year
- ASMB 2010
- VGI N/A
- Fundamental
- Price
- ASMB $18.09
- VGI $7.89
- Analyst Decision
- ASMB Strong Buy
- VGI
- Analyst Count
- ASMB 3
- VGI 0
- Target Price
- ASMB $33.00
- VGI N/A
- AVG Volume (30 Days)
- ASMB 44.2K
- VGI 46.0K
- Earning Date
- ASMB 08-07-2025
- VGI 01-01-0001
- Dividend Yield
- ASMB N/A
- VGI 12.66%
- EPS Growth
- ASMB N/A
- VGI N/A
- EPS
- ASMB N/A
- VGI N/A
- Revenue
- ASMB $32,154,000.00
- VGI N/A
- Revenue This Year
- ASMB $0.04
- VGI N/A
- Revenue Next Year
- ASMB N/A
- VGI N/A
- P/E Ratio
- ASMB N/A
- VGI N/A
- Revenue Growth
- ASMB 148.33
- VGI N/A
- 52 Week Low
- ASMB $7.75
- VGI $6.68
- 52 Week High
- ASMB $19.93
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- ASMB 64.35
- VGI 63.10
- Support Level
- ASMB $17.76
- VGI $7.82
- Resistance Level
- ASMB $18.99
- VGI $7.97
- Average True Range (ATR)
- ASMB 0.80
- VGI 0.07
- MACD
- ASMB -0.08
- VGI 0.01
- Stochastic Oscillator
- ASMB 63.86
- VGI 82.98
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.